Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1988 1
1989 3
1990 1
1991 7
1992 6
1993 5
1994 1
1995 2
1996 3
1997 3
1998 4
1999 1
2000 2
2001 6
2002 6
2003 7
2004 4
2005 1
2006 8
2007 8
2008 8
2009 3
2010 6
2011 13
2012 3
2013 13
2014 7
2015 14
2016 12
2017 14
2018 13
2019 14
2020 19
2021 18
2022 12
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primitive Neuroectodermal Tumor"
Page 1
Advancing therapy for neuroblastoma.
Qiu B, Matthay KK. Qiu B, et al. Nat Rev Clin Oncol. 2022 Aug;19(8):515-533. doi: 10.1038/s41571-022-00643-z. Epub 2022 May 25. Nat Rev Clin Oncol. 2022. PMID: 35614230 Review.
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. ...Other trials are focused on testing precision medicine strategies for patients with relapsed and/or …
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regres …
Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K, Taylor MD. Juraschka K, et al. J Neurosurg Pediatr. 2019 Oct 1;24(4):353-363. doi: 10.3171/2019.5.PEDS18381. J Neurosurg Pediatr. 2019. PMID: 31574483 Review.
Medulloblastoma is the most common pediatric malignant brain tumor. Advances in molecular profiling have uncovered significant heterogeneity among medulloblastomas and led to the identification of four distinct subgroups (wingless [WNT], sonic hedgehog [SHH], group 3, and …
Medulloblastoma is the most common pediatric malignant brain tumor. Advances in molecular profiling have uncovered significant hetero …
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG, Macy ME, Henderson TO. DuBois SG, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783. Am Soc Clin Oncol Educ Book. 2022. PMID: 35522915 Free article. Review.
We review current efforts to try to improve outcomes in patients with newly diagnosed disease by integrating novel targeted therapies earlier in the course of the disease. We further examine a growing list of options available for patients with relapsed or refractory …
We review current efforts to try to improve outcomes in patients with newly diagnosed disease by integrating novel targeted therapies earlie …
Gangliosides and Neuroblastomas.
Schengrund CL. Schengrund CL. Int J Mol Sci. 2020 Jul 27;21(15):5313. doi: 10.3390/ijms21155313. Int J Mol Sci. 2020. PMID: 32726962 Free PMC article. Review.
Much of the survival rate reflects age of diagnosis with children under a year having a much better prognosis than those over two. Identification of expression of GD2 on the surface of most NB cells led to studies of the effectiveness and subsequent approval of anti-GD2 an …
Much of the survival rate reflects age of diagnosis with children under a year having a much better prognosis than those over two. Id …
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Mody R, et al. J Clin Oncol. 2020 Jul 1;38(19):2160-2169. doi: 10.1200/JCO.20.00203. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343642 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients were eligible at first relapse or first designation of refractory disease. Oral T and intravenous (IV) irinotecan were administered on days 1 to 5 of 21-day cycles. ...CONCLUSION: I/T/DIN/GM-CSF has significant antitumor activity in patients …
PATIENTS AND METHODS: Patients were eligible at first relapse or first designation of refractory disease. Oral T and intravenous (IV) …
Childhood Medulloblastoma: An Overview.
Suk Y, Gwynne WD, Burns I, Venugopal C, Singh SK. Suk Y, et al. Methods Mol Biol. 2022;2423:1-12. doi: 10.1007/978-1-0716-1952-0_1. Methods Mol Biol. 2022. PMID: 34978683 Review.
Medulloblastoma (MB) is the most common malignant pediatric brain tumor, representing 60% of childhood intracranial embryonal tumors. ...Additionally, we detail how the cancer stem cell (CSC) hypothesis provides an explanation for tumor recurrence, and the po …
Medulloblastoma (MB) is the most common malignant pediatric brain tumor, representing 60% of childhood intracranial embryonal tumo …
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A. Levy AS, et al. Pediatr Blood Cancer. 2021 Aug;68(8):e29031. doi: 10.1002/pbc.29031. Epub 2021 Apr 12. Pediatr Blood Cancer. 2021. PMID: 33844469 Free PMC article. Clinical Trial.
This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, irinotecan, and bevacizumab for recurrent MB/central nervous system (CNS) primitive neuroectodermal tumor (PNET). METHOD …
This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, i …
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I. Peyrl A, et al. JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. JAMA Oncol. 2023. PMID: 37883081 Free PMC article. Clinical Trial.
IMPORTANCE: Medulloblastoma recurrence in patients who have previously received irradiation has a dismal prognosis and lacks a standard salvage regimen. OBJECTIVE: To evaluate the response rate of pediatric patients with medulloblastoma recurrence using an antiangiogenic m …
IMPORTANCE: Medulloblastoma recurrence in patients who have previously received irradiation has a dismal prognosis and lacks a standa …
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
BACKGROUND: Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in these patients, and its acceptable toxicity profile makes it an excellent backbone for study of new agents. ...Patients o …
BACKGROUND: Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomi …
Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma.
Tang XX, Shimada H, Ikegaki N. Tang XX, et al. Genes Immun. 2022 Jun;23(3-4):129-140. doi: 10.1038/s41435-022-00172-w. Epub 2022 May 7. Genes Immun. 2022. PMID: 35525858 Free PMC article.
Neuroblastoma is the most common extracranial childhood solid tumor. The majority of high-risk neuroblastoma is resistant/refractory to the current high intensity therapy. ...High-level expression of PD-L1 was found significantly associated with better outcome of hi …
Neuroblastoma is the most common extracranial childhood solid tumor. The majority of high-risk neuroblastoma is resistant/refracto …
242 results